Stock FBLG FIBROBIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News FibroBiologics, Inc.

Equities

FBLG

US31573L1052

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/05/2024 BST 		5-day change 1st Jan Change
11.99 USD +4.44% Intraday chart for FibroBiologics, Inc. +9.00% 0.00%
05-14 FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
FibroBiologics Announces 2024 Annual Meeting of Stockholders
GL
FibroBiologics Files 2024 First Quarter Report
GL
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
FibroBiologics to Present at the BIO International Convention 2024
GL
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
GL
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids
CI
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
GL
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
GL
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA
CI
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
GL
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply
MT
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
PR
FibroBiologics to Present at Advanced Wound Care Summit USA
PR
FibroBiologics Appoints Ruben A. Garcia as General Counsel
PR
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel
CI
FibroBiologics Files 2023 Form 10-K Annual Report
PR
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Premarket Gainers
MT
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum
AQ
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FBLG Stock
  4. News FibroBiologics, Inc.